Clinicogenetic risk models to predict outcome of follicular lymphoma patients
Which is the best combination therapy in relapsed and refractory multiple myeloma?
How the treatment of ALL is changing
What’s next for inotuzumab ozogamicin in ALL?
Follow-up CAR T-cell data so far